endostar

Endostar (recombinant human endostatin injection) is a Chinese-developed anti-tumor angiogenesis drug. It was created by adding nine amino acids to the original endostatin protein, resulting in improved stability and efficacy. Endostar specifically targets tumor blood vessels by inhibiting endothelial cell migration and inducing apoptosis of endothelial cells, thereby suppressing tumor angiogenesis and growth[2][3][8]. It was approved in China in 2005 for use in combination with vinorelbine/cisplatin chemotherapy as first-line treatment for advanced non-small cell lung cancer (NSCLC)[2][5]. The drug has also been explored for other cancers and malignant pleural effusion[6].

Brand names

Endostar恩度

Other names

重组人血管内皮抑素recombinant human endostatinEndostatin